TaiMed Biologics Inc (中裕新藥) yesterday said that it plans to market its Trogarzo HIV treatment in Germany by the end of this year, expressing confidence that it would obtain marketing approval from European regulators in October.
The European Medicines Agency’s (EMA) human medicines committee had a positive opinion on Trogarzo at a meeting on Friday last week, TaiMed chief financial officer Jack Chen (陳怡成) said.
That is important for TaiMed’s business in Europe, as the European Commission takes the committee’s recommendation into account when deciding on marketing approval for new treatments, Chen said.
“If everything goes smoothly, it is likely that we will receive marketing approval in early October,” Chen said.
TaiMed and its business partner, Canada-based Theratechnologies Inc, have decided that Germany would be Trogarzo’s first European market, he said.
Germany has a high income per capita and its regulations on drug prices are more friendly to pharmaceutical companies, he said.
Drug companies there can market their products before wholesale prices are finalized by the regulator, unlike other European markets, he added.
The price of Trogarzo is set at US$118,000 for a year of treatment in the US, but it is expected to fall by 25 to 35 percent in European markets, Chen said.
Theratechnologies, which helps sell Trogarzo in the US, would be responsible for negotiating the price with local regulatory bodies in Europe, he said.
As TaiMed did not conduct any clinical trials in Europe and used the data generated from its trials in the US for the European review, it is required by EMA to establish a mechanism to monitor local patients and to collect data, Chen said.
TaiMed has seen US sales of Trogarzo rise since the US Food and Drug Administration approved the treatment in March last year, he said.
The company posted cumulative revenue of NT$283 million (US$9.1 million) in the first half of this year, up 638 percent year-on-year, thanks to the rising sales of Trogarzo in the US, Chen said.
European sales are expected to boost whole-year revenue to about NT$800 million, he added.
Contract manufacturer WuXi Biologics Co (無錫生物製藥) would be responsible for the production of Trogarzo for European markets, as TaiMed’s new contract manufacturing partner Samsung BioLogics Co’s new plant in Hsinchu County’s Jhubei City (竹北) is still preparing for production, Chen said.
In the US clinical trial, Trogarzo was proven to have a long-lasting impact on HIV-1, with 83 percent of patients reducing their HIV-1 viral load after receiving a single dose of the drug, the company said.
SIZE MATTERS: Medium-sized hotels that do not have the support of parent groups are more vulnerable and are forced to take action, a REPro Knight Frank researcher said About 50 hotels across Taiwan are seeking to exit the market as they succumb to the bleak business outlook amid international travel restrictions imposed to combat the COVID-19 pandemic. Yomi Hotel (優美飯店) on Minsheng E Road, Sec 1, in Taipei is seeking to transfer ownership with an asking price of NT$950 million (US$32.15 million) and a pledge for a lease contract that guarantees a 3 percent return. The budget hotel, with room rates that start from NT$1,400 per night, maintains normal operations, but has been struggling since March, when the government placed restrictions on inbound and outbound travel. Occupancy rates for hotels in
With the US dollar expected to weaken in the next 12 months due to near-zero interest rates, investors should consider purchasing US corporate bonds, Standard Chartered Bank Taiwan Ltd (渣打台灣銀行) said on Thursday. The bank said that the US Federal Reserve since last month has been buying bonds issued by US companies to curb default rates. The US dollar is forecast to be weaker against the pound, the euro and the yen, as well as the Canadian dollar, the Swedish krona and the Swiss franc, as the greenback lacks high investment returns after the Fed in March slashed the benchmark interest rate
A Bollywood actor’s face tattooed on his arm, Sandeep Bacche’s devotion shocks few in India where stars enjoy semi-divine status, but even there the hallowed silver screen might be losing its shine to streaming services and pandemic fears. “Whenever things get better and theaters begin operations, I will watch three movies a day for sure just as a way to celebrate,” said the Mumbai rickshaw driver, who is recovering from the virus himself. However, others might not join the party. With cinemas shut for months due to a COVID-19 lockdown, and little prospect they will reopen soon, frustrated Bollywood producers have turned to
Polytronics Technology Corp (聚鼎科技) yesterday announced that it is buying Henkel AG’s thermal clad dielectric material (TCLAD) business division for US$26 million as the Taiwanese firm aims to improve its technology, product portfolio and revenue performance. Polytronics, headquartered in the Hsinchu Science Park (新竹科學園區), is a supplier of protection components and heat dissipation materials. The firm entered the metallic heat-dissipation substrate market in 2007 and developed a unique solventless production process. Its board of directors approved signing an agreement with Henkel to acquire the German chemical firm’s TCLAD division in the US. The purchase includes all assets and business interests, including equipment,